uploads/2018/01/Ana-Reco-Insys-1.png

What Analysts Recommend for Insys Therapeutics and Peers

By

Updated

Company overview

Insys Therapeutics (INSY) is a commercial-stage specialty pharmaceutical company headquartered in Chandler, Arizona. The company is focused on developing and commercializing innovative products in the supportive care segment.

Insys currently has two products on the market:

  • Subsys, which was launched in March 2012, is a sublingual fentanyl spray for breakthrough cancer pain (or BTCP) in patients who are opioid-tolerant.
  •  Syndros, which was launched in July 2017, is an orally administered liquid formulation for the treatment of chemotherapy-induced nausea and vomiting (or CINV) and weight loss in patients with AIDS.

Insys primarily sells Subsys and Syndros to pharmaceutical wholesalers. Sales to the company’s three largest wholesale customers accounted for 54% of gross revenues in the first three quarters of fiscal 2017.

 

Article continues below advertisement

Analyst recommendations

Of the six analysts covering Insys in January 2018, four analysts have given the company a “buy” or higher rating, while two analysts have given the stock a “hold” rating. The mean rating for the stock is two with a target price of $9.8. Insys makes up about 0.10% of the iShares Nasdaq Biotechnology ETF’s (IBB) total portfolio holdings.

Peer ratings

Of the total 31 analysts covering GlaxoSmithKline (GSK) in January 2018, 12 analysts have given the company a “buy” or a higher rating. The mean rating for the stock is 2.6 with a target price of $1,542.79.

Of the total 23 analysts covering Merck (MRK) in January 2018, 13 analysts have given the stock a “buy” or a higher rating. The mean rating for the stock is 2.2 with a target price of $65.41.

Of the total 29 analysts covering Teva (TEVA) in January 2018, six analysts have given the stock a “buy” or higher rating, while six analysts have given the stock a “sell” or lower rating. The mean rating for the stock is 3.0 with a target price of $18.72.

In the next part of the series, we’ll take a look at the financial performance of Insys.

 

Advertisement

More From Market Realist